- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Journal: Survey of community pharmacists' opinions on drug scheduling in Ontario and Qu (Pubmed Central) - Aug 14, 2024 Ontario pharmacists expressed a preference for scheduling change for five drugs (four prescription [terconazole for intravaginal use, famotidine, rupatadine, mometasone nasal spray] and one unscheduled [ranitidine 75 mg]), while Qu
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Journal: Antihistamines H1 as Potential Anthelmintic Agents against the Zoonotic Parasite Angiostrongylus cantonensis. (Pubmed Central) - Jul 22, 2024 The findings revealed four active compounds (promethazine, cinnarizine, desloratadine, and rupatadine), with promethazine demonstrating the highest potency (EC50 = 31.6 ?M)...Furthermore, an analysis of the physicochemical and pharmacodynamic properties of antihistamines revealed that their anthelmintic activity does not correlate with their activity at H1 receptors. This study marks the first documentation of antihistamines' activity against A. cantonensis, offering a valuable contribution to the quest for novel agents effective against zoonotic helminths.
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
The PAF inhibitor Rupatadine has a positive influence on clinical and laboratory findings in patients with urticarial vasculitis (Poster Zone) - Apr 21, 2024 - Abstract #EAACI2024EAACI_1581; Conclusion In patients with HUV rupatadine competitively inhibits PAF-induced platelet aggregation with significant anti-inflammatory effects and suppression of inflammatory cytokines synthesis by activated T lymphocytes, and reduced degranulation and release of histamine and other cytokines by cutaneous mast cells . Rupatadine also induced improvement in HUV-patient life quality compared to other second-generation antihistamines.
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Journal: Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial. (Pubmed Central) - Aug 19, 2023 Our results provide compelling preclinical evidence supporting the potential use of CZ as a modulator of the MDM2-p53 axis and its plausible repurposing for cancer treatment. Daily rupatadine treatment significantly improved CSU disease activity and QoL during treatment versus OD treatment but not after discontinuation of rupatadine, indicating the benefits of a daily maintenance nsAH schedule.
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Acquired angioedema with C1-inhibitor deficiency (AAE-C1-INH) (Poster Zone A) - May 13, 2023 - Abstract #EAACI2023EAACI_1980; Skin histopathological assessment revealed smooth epidermis, with segmental vacuole degeneration of the basal layer and basal hyperpigmentation. Moreover, presence of perivascular clusters of inflammatory cells, mainly granulocytes and lymphocytes with additional presence of dispersed neutrophils has been ascertained.
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Hypersensitivity to erythritol in a 7-year-old boy (Poster Zone C) - Apr 30, 2023 - Abstract #EAACI2023EAACI_1622; Conclusions When looking for the causative agents of anaphylactic reactions to food, one should remember food additives, including the commonly used erythritol. This is of particular importance in the developmental age population, as erythritol is sometimes used as a sweetener in syrups.
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Trial completion, Trial completion date: A Comparative Study of Rupatadine 10 mg Tablets and Clarinex (clinicaltrials.gov) - Mar 23, 2023 P1, N=45, Completed, Only cetirizine and rupatadine up-dosing have been documented to be effective and safe in children, while there is lack of data on geriatric patients and pregnant or lactating females. Active, not recruiting --> Completed | Trial completion date: May 2022 --> Jan 2023
- |||||||||| cetirizine oral / Generic mfg., Rupex (rupatadine) / Incepta Pharma, Medexus, desloratadine / Generic mfg.
Preclinical, Journal: Effects of second-generation H1-antihistamine drugs on angiogenesis in in (Pubmed Central) - Mar 9, 2023 Active, not recruiting --> Completed | Trial completion date: May 2022 --> Jan 2023 To investigate the effects of cetirizine, desloratadine, and rupatadine (second-generation H1-antihistamines commonly used in dermatology clinics) on angiogenesis in an in
- |||||||||| fluconazole oral / Generic mfg., itraconazole / Generic mfg.
Journal, Real-world evidence, Real-world: Real world co-prescribing contraindicated drugs with fluconazole and itraconazole. (Pubmed Central) - Feb 22, 2023 Many co-prescriptions were associated with the risk of DDI-related QTc prolongation, warranting the attention of healthcare providers. Narrowing the discrepancy between databases that provide information on DDIs is required for optimized medicine usage and patient safety.
- |||||||||| paracetamol / Generic mfg.
Biphasic Allergy to Acetaminophen: An Additional Appearance in the Post-Delivery Population (Exhibit Hall (Upper Concourse); Monitor 03) - Oct 10, 2022 - Abstract #ACAAI2022ACAAI_869; She was confirmed as having an acetaminophen-induced allergic reaction and treated with rupatadine at 10 mg and recovered...Ambulance emergency services treated her with diphenhydramine and ER transport...Discussion This case illustrates a biphasic reaction to acetaminophen initially presenting post-delivery, a rare occurrence, in a patient previously tolerant to acetaminophen. In clinics choosing to test acetaminophen allergy, patients that fail oral challenge should be provided a care plan and education on how to treat any delayed reactions that may appear without allergen re-exposure.
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Journal: Incorporation of Ethylcellulose Microparticles Containing a Model Drug with a Bitter Taste into Nanofibrous Mats by the Electrospinning Technique-Preliminary Studies. (Pubmed Central) - Aug 14, 2022 Owing to the potential use of electrospun nanofibers as an orodispersible drug dosage form, ethylcellulose microparticles containing the antihistamine drug rupatadine fumarate, prepared by the spray drying technique to conceal the drug's bitter taste, were incorporated into nanofibers...SEM image analysis has shown that the nanofibers were homogeneous and smooth and possessed a fast disintegration time (below 30 s) and an adequate drug content with a simultaneous taste-masking effect (as indicated by the in vivo and in vitro methods). However, further studies are necessary to refine their mechanical characteristics.
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Journal: Repurposing Histaminergic Drugs in Multiple Sclerosis. (Pubmed Central) - Jun 19, 2022 We have identified new histamine drug-disease associations and predicted off-label novel use of the histaminergic drugs amodiaquine, rupatadine, and diphenhydramine among others, for multiple sclerosis. Our work suggests that selected histamine-related molecules might get to the root causes of multiple sclerosis and emerge as new potential therapeutic strategies for the disease.
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Preclinical, Journal: Role of Platelet-activating factor and HO-1 in mediating the protective effect of rupatadine against 5-fluorouracil-induced hepatotoxicity in rats. (Pubmed Central) - May 25, 2022 RU ameliorated 5-FU-induced liver damage as proved by the improved serum ALT, AST, and hepatic oxidative stress parameters, the attenuated expression of hepatic pro-inflammatory cytokines and PAF, and the up-regulation of HO-1. Therefore, it can be concluded that RU pretreatment exerted a hepatoprotective effect against 5-FU-induced liver damage through both its powerful anti-inflammatory, antioxidant, and anti-apoptotic effect.
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Clinical, Journal: Rupatadine to prevent local allergic reactions to sublingual allergy immunotherapy: a case series. (Pubmed Central) - Dec 7, 2021 In the cases presented, treatment with rupatadine resolved LAR associated with SLIT-T treatment and rupatadine pretreatment appeared to mitigate subsequent LAR. Rupatadine may be an option to treat or improve the tolerability of the SLIT-T, potentially improving early treatment persistence.
|